GLP-1 medication for psoriatic arthritis outcomes
Part of Bones, joints & muscles, Skin clinical trials.
This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have psoriatic arthritis (diagnosed by a doctor)
- Your BMI is 30 or higher
- Your psoriatic arthritis is not well-controlled (not in a state called 'minimal disease activity')
- You have never taken a GLP-1 medication (like Ozempic or Wegovy) before
- You are willing to start a GLP-1 medication as part of this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a weight-loss medication (tirzepatide) to a biologic (ixekizumab) helps people with psoriatic arthritis and overweight or obesity. You will need to have biopsies of joint tissue and fat to see how the treatment affects inflammation.
This trial tests an experimental drug called FT2109 for people with psoriatic arthritis, a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if FT2109 can reduce symptoms and improve quality of life.
This study tests whether a medicine called a GLP-1 receptor agonist (a type of drug often used for weight and diabetes) can help people with psoriatic arthritis who are overweight but not diabetic. It may reduce joint symptoms and help with weight loss.
This study tests a drug that helps with weight loss and blood sugar (called a GLP-1 receptor agonist) combined with a special diet to see if it can improve symptoms in people with mild Crohn's disease. You may join if you have Crohn's, a BMI of 27 or higher, and are already on a stable dose of a TNF blocker.
This study looks at how GLP-1 receptor agonist drugs (used for weight loss) affect muscle mass and strength in people with obesity who do not have diabetes. It may help understand if these medications impact muscle health.
This study looks at whether a type of diabetes medicine called GLP-1 analogues (like Ozempic) might affect the risk of developing osteoarthritis (a common type of arthritis that wears down joints). If you have type 2 diabetes and have been taking either a GLP-1 medicine or another type called SGLT2 inhibitors for at least a year, this trial may help you understand your joint health.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.